Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AGER | Q15109 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1854742 | 0.99 | TSHR (0.43) | TSHRALDH1A1NPC1LMNAKDM4E | |
| SCHEMBL1855269 | 0.83 | TSHR (0.40) | TSHRALDH1A1NPC1LMNAKDM4E | |
| SCHEMBL1857716 | 0.75 | GRM2 (0.39) | TSHRALDH1A1NPC1GRM2 | |
| Hydrochloric Acid SCHEMBL1858945 | 0.74 | GRM2 (0.39) | TSHRALDH1A1NPC1GRM2 | |
| SCHEMBL29617939 | 0.72 | TRPC5 (0.38) | TSHRALDH1A1NPC1LMNAHTT | |
| SCHEMBL13355261 | 0.71 | ALDH1A1 (0.47) | TSHRALDH1A1NPC1LMNAKDM4E | |
| SCHEMBL1865108 | 0.71 | CYP1A2 (0.53) | TSHRALDH1A1NPC1LMNAGRM2 | |
| Hydrochloric Acid SCHEMBL4918750 | 0.70 | CYP1A2 (0.51) | TSHRALDH1A1NPC1LMNAGRM2 | |
| SCHEMBL12628760 | 0.68 | GRM2 (0.70) | TSHRALDH1A1NPC1KDM4EHSD17B10 | |
| SCHEMBL1856433 | 0.66 | LMNA (0.61) | TSHRALDH1A1LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794154-B1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2007104772-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104772-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007093608-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093608-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1794154-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032627-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | CHRM1, ADRB1, ADRA1B | TSHR 917/4885ALDH1A1 1726/4885NPC1 1822/4885 |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | ADRB1, ADRB2, ADRA1B | TSHR 790/4885ALDH1A1 2339/4885NPC1 1135/4885 |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | CHRM1, CHRM2, MTNR1B | TSHR 1644/4885ALDH1A1 993/4885NPC1 712/4885 |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM1, CHRM2, MTNR1B | TSHR 1644/4885ALDH1A1 993/4885NPC1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.